Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcing the company has passed a major milestone for its Azer-cel therapy treatment with the dosing of the first patient for its Phase 1b Allogeneic CAR T Clinical Trial. It follows a Phase 1a trial that included 84 patients across leading US healthcare centres and offered strong safety and efficacy signals according to IMU. The second part of this Phase 1 trial involves the study of Azer-cel in an ongoing, multi-centre clinical trial in patients with non-Hodgkins lymphoma blood cancer, and serves as a precursor to Phase 2 registrational (subject to FDA approval) in 2024.
It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology, Chong said.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/imugene-says-azer-cel-could-be-best-in-class-allogeneic-car-t-421401816
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Press Echo 360 journalist was involved in the writing and production of this article.